AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
SGH’s A$13.15 Billion BlueScope Bid Sparks Steel Sector Shake-Up and Share Price Surge 
Chinese EV Stocks Slide as December Sales Growth Slows, Raising Demand Concerns 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
Dell Revives XPS Laptop Lineup With New XPS 14 and XPS 16 to Boost Premium PC Demand 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
TSMC Shares Hit Record High as Goldman Sachs Raises Price Target on AI Demand Outlook 
SMIC Shares Climb as China Boosts Chipmaking Support Amid AI Optimism 
Cathay Pacific Shares in Focus as Air China Plans Major Stake Reduction 
Grok AI Controversy on X Sparks Global Outrage Over Nonconsensual Images 
Samsung Electronics Poised for Massive Q4 Profit Surge on Soaring Memory Chip Prices 
Nvidia Unveils Rubin Platform to Power Next Wave of AI Infrastructure 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
WALTHAM, Mass., Oct. 23, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Credit Suisse 26th Annual Healthcare Conference at The Phoenician in Scottsdale, Arizona on Monday, November 6 and Tuesday, November 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat at 10:55 AM MT on Tuesday, November 7, and will also host meetings with investors.
- The Evercore ISI BioPharma Catalyst/Deep Dive Conference at the Boston Harbor Hotel in Boston on Wednesday, November 29. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat from 3:50 to 4:35 PM ET on Wednesday, November 29, and will also host meetings with investors.
Live webcasts of the presentations at the Credit Suisse and Evercore ISI conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
Vice President, Corporate Communications & Investor Relations
+1.781.325.1116 or [email protected]
